Il principale motore di ricerca di sperimentazioni cliniche in Europa

CYCLOHEXANECARBOXYLIC ACID, 4-[(2,5-DIHYDRO-2,5-DIOXO-1H-PYRROL-1- YL)METHYL]-, 2-[2-[[O-6-DEOXY-ALFA-L-GALACTOPYRANOSYL-(1->2)-O- BETA-D-GALACTOPYRANOSYL-(1->3)-O-2-(ACETYLAMINO)-2-DEOXY-BETA-D-GALACTOPYRANOSYL-(1->3)-O-ALFA-D-GALACTOPYRANOSYL-(1->4)-O- Β-D-GALACTOPYRANOSYL-(1->4)-BETA-D- GLUCOPYRANOSYL]OXY]ETHYL]HYDRAZIDE, REACTION PRODUCTS WITH HEMOCYANIN KEYHOLE LIMPET

FAQ

Sperimentazioni cliniche in corso su CYCLOHEXANECARBOXYLIC ACID, 4-[(2,5-DIHYDRO-2,5-DIOXO-1H-PYRROL-1- YL)METHYL]-, 2-[2-[[O-6-DEOXY-ALFA-L-GALACTOPYRANOSYL-(1->2)-O- BETA-D-GALACTOPYRANOSYL-(1->3)-O-2-(ACETYLAMINO)-2-DEOXY-BETA-D-GALACTOPYRANOSYL-(1->3)-O-ALFA-D-GALACTOPYRANOSYL-(1->4)-O- Β-D-GALACTOPYRANOSYL-(1->4)-BETA-D- GLUCOPYRANOSYL]OXY]ETHYL]HYDRAZIDE, REACTION PRODUCTS WITH HEMOCYANIN KEYHOLE LIMPET

  • Studio di Fase 3 su Adagloxad Simolenin per il Trattamento del Cancro al Seno Triplo Negativo in Stadio Iniziale ad Alto Rischio

    Arruolamento concluso

    3 1 1 1
    Malattie in studio:
    Farmaci in studio:
    Polonia